FORT COLLINS, Colo., Oct. 4, 2023 /PRNewswire/ — Armis Biopharma, Inc. announced today that the company received a $20.3 million contract from the Defense Threat Reduction Agency (DTRA) to develop its proprietary Veriox® DECON chemical warfare agent (CWA) decontamination product for use in battlefield wounds. This will be an important…Read More
Armis Biopharma Announces Receipt of a 203 Million Contract with the Defense Threat Reduction Agency to Develop Veriox DECON for Battlefield Wounds
